home / stock / obsv / obsv news

OBSV News and Press, ObsEva SA From 05/20/21

Stock Information
Company Name: ObsEva SA
Stock Symbol: OBSV
Market: NASDAQ
Website: obseva.com
Menu
OBSV OBSV Quote OBSV Short OBSV News OBSV Articles OBSV Message Board
Get OBSV Alerts

News, Short Squeeze, Breakout and More Instantly...
OBSV - SPCE, RIOT, ONCT and HIMS among premarket gainers

Virgin Galactic Holdings (SPCE) +21% after test flight scheduled for May 22VistaGen Therapeutics (VTGN) +15% after Baird calls stock 'significantly undervalued'.Allogene Therapeutics (ALLO) +13% on positive early-stage data for CAR T candidates in blood cancer.PDS Biotechnology...
OBSV - ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of Yselty® (linzagolix) for the Treatment of Uterine Fibroids

- PRIMROSE 1 76-week results confirm PRIMROSE 2 data showing sustained post- treatment effects and evidence of bone mineral density (BMD) recovery following 52 weeks of treatment - - Results c ontinue to support the differentiated profil...

OBSV - IDEX, DISCA, MNMD and ATOS among premarket gainers

Discovery DISCK +24% on definitive agreement with AT&T.Aerpio Pharmaceuticals ARPO +20% on merger deal with Aadi Bioscience.Nuvve Holding Corp. (NVVE) +16%.Aterian (ATER) +13%.Net Element (NETE) +13%.Mind Medicine MNMD +12% on receiving FDA Type C meeting res...

OBSV - ObsEva Announces First Quarter 2021 Financial Results and Business Update

- Yselty ® for uterine fibroids: US New Drug Application submission planned in Q 3 :21 ; European marketing approval recommendation anticipated in Q4:21 - - Yselty ® for endometriosis: Readou...
OBSV - ObsEva appoints Clive Bertram as Chief Commercial Officer

GENEVA, Switzerland and BOSTON, MA – May 6 , 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the appointment of Clive Bertram as C...

OBSV - ObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain

- EDELWEISS 3 t rial of Yselty ® e xpected to r eport t opline d ata as planned in Q4:21- GENEVA, Switzerland and BOSTON, MA – May 4 , 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBS...

OBSV - ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021

GENEVA, Switzerland and BOSTON, MA – April 30, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN) a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the presentation of five e-Posters o...
OBSV - ObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 Trial Participants

- Long-term follow-up study to evaluate bone mineral density in women completing at least 20 weeks of treatment in Phase 3 PRIMROSE 1 or PRIMROSE 2 - GENEVA, Switzerland and BOSTON, MA – April 27 , 2021 – ObsEva SA (NASDAQ:...

OBSV - ObsEva Annual General Meeting 2021

Geneva, Switzerland and Boston, MA – April 22 , 202 1 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today published ...

OBSV - ObsEva readies $50 million worth common stock offering

ObsEva ([[OBSV]] +9.3%) has entered into a sales agreement with SVB Leerink to sell the common stock for total gross proceeds of up to $50M, the company has said in a regulatory filing.SVB Leerink will be the sales agent for at the market offering where the company expects to sell the co...
Previous 10 Next 10